MedTrace Logo

Evaluation of Immediate Release Tablet

NCT02808741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-11-28

No results posted yet for this study

Summary

Single dose comparison of liquid and solid formulation, followed by study of effect of high fat breakfast.

Evaluation of multiple dose pharmacokinetics and tolerability

Conditions

  • Invasive Aspergillosis

Interventions

DRUG

F901318 SDD

Pharmacokinetics area under curve

DRUG

F901318 IR

Pharmacokinetics area under curve

DRUG

F901318 IR Fasting

Pharmacokinetics area under curve

DRUG

F901318 IR Fed

Pharmacokinetics area under curve

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • F2G Biotech GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02808741 on ClinicalTrials.gov